Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol

Background The therapeutic landscape for spinal muscular atrophy has changed in the last few years, encompassing respiratory/motor function and life expectancy benefits. However, physicians still have the challenge of tailoring individuals’ treatment to therapeutic goals, disease progression, patient/caregiver’s preferences, and personal experience to achieve an optimal risk/benefit balance. This study aims to provide insight into the preferred treatment choices of pediatric neurologists managing spinal muscular atrophy in their daily practice and to recognize behavioral factors that may influence decision-making. Methods This is a noninterventional, cross-sectional pilot study involving 50 pediatric neurologists managing spinal muscular atrophy in Spain. We designed an online platform that contains 13 simulated case scenarios of common presentations of patients with spinal muscular atrophy. The primary study outcome will be treatment preferences according to the percentages of participants who select treatment initiation when recommended, switch therapies when there is evidence of disease progression, and select treatment discontinuation when disease progression puts patients outside treatment recommendation (11 case scenarios). Secondary outcomes include therapeutic inertia prevalence (11 case scenarios), herding phenomenon prevalence (2 case scenarios), care-related regret prevalence (specific questions) and intensity (10-item Regret Intensity Scale), occupational burnout prevalence (nonproprietary single-item measure), and risk preferences (uncertainty test and risk aversion assessment). Conclusions The study findings will contribute to better understand relevant factors associated with therapeutic decisions of pediatric neurologists in spinal muscular atrophy, identifying treatment preferences and evaluating the role of behavioral aspects such as therapeutic inertia, herding, regret, and workplace burnout.

[1]  A. Izenberg,et al.  A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method , 2021, Journal of neuromuscular diseases.

[2]  J. Visser-Meily,et al.  Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy , 2021, Developmental medicine and child neurology.

[3]  J. Maurino,et al.  Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study) , 2021, Neurology and Therapy.

[4]  L. Servais,et al.  Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study , 2020, Annals of clinical and translational neurology.

[5]  E. Tizzano,et al.  Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy , 2020, Neurology: Genetics.

[6]  K. Lombarts,et al.  Associations between job demands, job resources and patient-related burnout among physicians: results from a multicentre observational study , 2020, BMJ Open.

[7]  W. Arnold,et al.  Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment , 2020, Orphanet Journal of Rare Diseases.

[8]  R. Finkel,et al.  Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy , 2020, Frontiers in Neurology.

[9]  A. Ziegler,et al.  European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy , 2020, European Journal of Paediatric Neurology.

[10]  S. Messina,et al.  New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges , 2020, Journal of clinical medicine.

[11]  L. Belter,et al.  Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey , 2020, Orphanet Journal of Rare Diseases.

[12]  R. Finkel,et al.  Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2 , 2020, Journal of neuromuscular diseases.

[13]  G. Saposnik,et al.  Factors associated with therapeutic inertia among pharmacists caring for people with multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[14]  Lindsey E. Carlasare,et al.  Relationship Between Burnout, Professional Behaviors, and Cost-Conscious Attitudes Among US Physicians , 2019, Journal of General Internal Medicine.

[15]  J. Kirschner,et al.  Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care , 2019, Journal of neuromuscular diseases.

[16]  R. Finkel,et al.  A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy , 2019, Neuromuscular Disorders.

[17]  Hanns Lochmüller,et al.  Quality of life of patients with spinal muscular atrophy: A systematic review. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  L. Belter,et al.  Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community. , 2019, Clinical therapeutics.

[19]  S. Kolb,et al.  Current Treatment Options in Neurology—SMA Therapeutics , 2019, Current Treatment Options in Neurology.

[20]  Hanns Lochmüller,et al.  SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy , 2019, Orphanet Journal of Rare Diseases.

[21]  T. Sejersen,et al.  Parents’ Experiences of Information and Decision Making in the Care of Their Child With Severe Spinal Muscular Atrophy: A Population Survey , 2019, Journal of child neurology.

[22]  S. Ashwal,et al.  Evidence in focus: Nusinersen use in spinal muscular atrophy , 2018, Neurology.

[23]  X. Montalban,et al.  Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care , 2018, Front. Neurol..

[24]  R. Finkel,et al.  Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics , 2017, Neuromuscular Disorders.

[25]  W. Chung,et al.  Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care , 2017, Neuromuscular Disorders.

[26]  Hanns Lochmüller,et al.  Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.

[27]  G. Bellis,et al.  Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients , 2017, Neuromuscular Disorders.

[28]  P. Tobler,et al.  Decision-making in Multiple Sclerosis: The Role of Aversion to Ambiguity for Therapeutic Inertia among Neurologists (DIScUTIR MS) , 2017, Front. Neurol..

[29]  P. Tobler,et al.  Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS , 2017, Patient preference and adherence.

[30]  Philippe N. Tobler,et al.  Cognitive biases associated with medical decisions: a systematic review , 2016, BMC Medical Informatics and Decision Making.

[31]  G. Saposnik,et al.  Decision making under uncertainty, therapeutic inertia, and physicians’ risk preferences in the management of multiple sclerosis (DIScUTIR MS) , 2016, BMC Neurology.

[32]  R. Finkel,et al.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials , 2015, Neuromuscular Disorders.

[33]  Shira Elqayam,et al.  Thinking Styles and Regret in Physicians , 2015, PloS one.

[34]  Stephan D. Fihn,et al.  Using a Single Item to Measure Burnout in Primary Care Staff: A Psychometric Evaluation , 2015, Journal of General Internal Medicine.

[35]  C. Fox,et al.  Time of day and the decision to prescribe antibiotics. , 2014, JAMA internal medicine.

[36]  Sherrill L. Sellers,et al.  Physicians’ Anxiety Due to Uncertainty and Use of Race in Medical Decision Making , 2014, Medical care.

[37]  Sean J. Taylor,et al.  Social Influence Bias: A Randomized Experiment , 2013, Science.

[38]  T. Rice.  The behavioral economics of health and health care. , 2013, Annual review of public health.

[39]  Chiara S. Haller,et al.  Validation of a 10-item Care-related Regret Intensity Scale (RIS-10) for Health Care Professionals , 2013, Medical care.

[40]  Yasser Salem.  Spinal muscular atrophy , 2010, Journal of the Neurological Sciences.

[41]  George I. Christopoulos,et al.  Neural Correlates of Value, Risk, and Risk Aversion Contributing to Decision Making under Risk , 2009, The Journal of Neuroscience.

[42]  R. Dolan,et al.  Brain, emotion and decision making: the paradigmatic example of regret , 2007, Trends in Cognitive Sciences.

[43]  R. Devellis,et al.  Physicians' Reactions to Uncertainty: Refining the constructs and scales , 1995 .

[44]  Colin Camerer,et al.  Recent developments in modeling preferences: Uncertainty and ambiguity , 1992 .

[45]  M S Gerrity,et al.  Physicians' Reactions to Uncertainty in Patient Care: A New Measure and New Insights , 1990, Medical care.

[46]  P. Glimcher,et al.  Title: the Neural Representation of Subjective Value under Risk and Ambiguity 1 2 , 2009 .